TOTAL ALLERGY CARE for HEALTH PROFESSIONALS
SIGN UP

Quality of Life

When managing allergy symptoms with ZYRTEC®, patients can get on with their day1*†

ZYRTEC® significantly improved patients’ allergy-related quality of life (QoL) vs placebo1*†‡

In large clinical studies using the Rhinoconjunctivitis Quality of Life Questionnaire (RQLQ), patients receiving ZYRTEC® reported greater improvements in RQLQ scores compared with placebo, including:

  • 80% greater improvement in QoL vs placebo2§
  • Significant reductions in impairment at work and with daily activities1*†

When taking ZYRTEC® to manage allergy symptoms, patients can get back to the things that are important to them.

About the RQLQ

The Rhinoconjunctivitis Quality of Life Questionnaire is a validated, allergy-specific measurement of overall QoL. Two of the studies with ZYRTEC® used the 28-question version of the RQLQ, which measures 7 domains||:

  • Activity limitation
  • Sleep problems
  • Nose symptoms
  • Eye symptoms
  • Non–hay fever symptoms
  • Practical problems
  • Emotional function

In both perennial and seasonal allergic rhinitis, ZYRTEC® significantly improved adult patients’ QoL vs placebo1-3§¶

Studies compared overall scores from the Rhinoconjunctivitis Quality of Life Questionnaire (RQLQ)

Adult patients with perennial allergic rhinitis (PAR)

This study used a 24-question version of the RQLQ that measured 6 allergy-related domains: activity limitation, sleep problems, nose symptoms, non-hay fever symptoms, practical problems, and emotional function.||

Adult patients with seasonal allergic rhinitis (SAR)

These studies used a 28-question version of the RQLQ that measured 7 allergy-related domains.

ZYRTEC® starts working at hour 1 the first day you take it; Claritin®, at hour 34,5**

Another reason to start with ZYRTEC®.

VIEW ONSET DATA

Free app helps patients manage allergies*

Symptom tracking, pollen forecasts, and more with ZYRTEC® ALLERGYCAST®.

*Standard data rates apply.

SEE APP

*Randomized, placebo-controlled, 2-week study of adult patients with seasonal allergic rhinitis (N=431 for each treatment group).

†Impact on self-reported activity impairment was assessed using the Work Productivity and Activity Impairment-Allergy Specific (WPAI-AS) questionnaire, which measures performance based on impairment at work (limitations in the amount or kind of work done, work accomplished, or work done as carefully as usual) and activity impairment (limitations in usual activities, such as work around the house, shopping, child care, exercising, etc).

‡Patient disease-specific quality of life was assessed using the Rhinoconjunctivitis Quality of Life Questionnaire (RQLQ), which measures 7 domains: activity limitation, sleep problems, nose symptoms, eye symptoms, non–hay fever symptoms, practical problems, and emotional function.

§Multicenter, randomized, double-blind, placebo-controlled study including 316 adult PAR patients. Primary study endpoint measured changes in overall RQLQ score from baseline.

||Adult RQLQ assessed domains on a 7-point (0-6) rating scale.6

¶Two multicenter, randomized, double-blind, placebo-controlled studies including 1254 adult SAR patients. Primary study endpoint measured changes in overall RQLQ score from baseline.

#Endpoint = last post-baseline observation.

**ZYRTEC® 10 mg starts working at hour 1 and Claritin® starts working at hour 3, based on first dose on the first day of a 2-day study in 2 pollen-chamber studies. Primary endpoint measured mean improvement from baseline in Major Symptom Complex (MSC) severity score. MSC symptoms included runny nose, sniffles, itchy nose, nose blows, sneezes, and watery eyes.

References: 1. Murray JJ, Nathan RA, Bronsky EA, Olufade AO, Chapman D, Kramer B. Comprehensive evaluation of cetirizine in the management of seasonal allergic rhinitis: impact on symptoms, quality of life, productivity, and activity impairment. Allergy Asthma Proc. 2002;23(6):392-398. 2. Data on file. Johnson & Johnson Consumer Inc., McNeil Consumer Health Division. 3. Noonan MJ, Raphael GD, Nayak A, et al. The health-related quality of life effects of once-daily cetirizine HCI in patients with seasonal allergic rhinitis: a randomized double-blind, placebo-controlled trial. Clin Exp Allergy. 2003;3(3):351-358. 4. Day JH, Briscoe M, Widlitz MD. Cetirizine, loratadine, or placebo in subjects with seasonal allergic rhinitis: effects after controlled ragweed pollen challenge in an environmental exposure unit. J Allergy Clin Immunol. 1998;101(5):638-645. 5. Day JH, Briscoe M, Rafeiro E, Chapman D, Kramer B. Comparative onset of action and symptom relief with cetirizine, loratadine, or placebo in an environmental exposure unit in subjects with seasonal allergic rhinitis: confirmation of a test system. Ann Allergy Asthma Immunol. 2001;87(6):474-481. 6. Juniper EF, Guyatt GH. Development and testing of a new measure of health status for clinical trials in rhinoconjunctivitis. Clin Exp Allergy.1991;21(1):77-83.